EMCTO 2013: Industry Sponsors
Tel: +41 61 688 11 11
Fax: +41 61 691 93 91
At Roche we focus on developing medicines and diagnostics that will help patients live longer, better lives. We strive to address unmet medical needs through excellence in science – from early detection and prevention of diseases to diagnosis, treatment and treatment monitoring. Tarceva (erlotinib) is a potent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of non-small cell lung cancer (NSCLC). Tarceva is also indicated, in combination with gemcitabine, for the treatment of patients with metastatic pancreatic cancer.
Lilly Export SA
Eli Lilly and Company
Lilly has remained dedicated to creating medicines that help improve peoples' quality of life for more than 135 years.
ALIMTA is registered in Europe for therapeutic indications in unresectable malignant pleural mesothelioma and for specific patients with other than predominantly squamous cell histology advanced nonsquamous non-small cell lung cancer
As EMCTO is a specific Lung Cancer related Congress, Lilly Oncology will promote ALIMTA in label. In addition, The results of the PARAMOUNT trial have shown that some patients with advanced nonsquamous non-small cell lung cancer may benefit from continuation maintenance treatment with ALIMTA single agent after first-line therapy with ALIMTA/cisplatin.
Route 206 and Province Line Road
08543 Princeton New Jersey
Tel : + 33 (0)1 58 83 60 00 (Europe)
Fax : + 33 (0)1 58 83 60 01 (Europe)
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail against serious diseases. Around the world, our medicines are helping millions of patients in their fight against such diseases as cancer, cardiovascular disease, diabetes, hepatitis B, HIV/AIDS, psychiatric disorders and rheumatoid arthritis. In addition, our philanthropic programmes have given new hope to some of the world’s most vulnerable people.
Novartis Pharma AG
Forum 1 - Novartis Campus
Tel: +39 02 96542989
Fax: +39 02 96542910
Novartis Oncology has emerged as a global leader in oncology through targeted research and open partnership in the pursuit of new therapies capable of transforming outcomes for people with cancer.
We offer a wide range of innovative therapies to help physicians meet patient needs, with one of the broadest and most comprehensive oncology pipelines in the industry. Our research is driven by a distinctive scientific and clinical strategy, focusing on unmet medical needs and disease pathways.
Tel: +41 43 495 71 11
Advances in cancer drug development now mean that the precise molecular profile of the tumour can guide treatment choice. Consequently, identifying patients with certain molecular alterations is crucial. Anaplastic lymphoma kinase (ALK) is an oncogenic driver that is present in some patients with advanced non-small cell lung cancer. (Soda M, et al Nature 2007;448:561–66)
www.alktesting.com is a new Pfizer-funded website designed for healthcare professionals interested in learning more about ALK and how to test for ALK. Visit the website for the latest information and watch expert oncologists and pathologists talk about ALK and ALK testing.
Sponsorship by Pfizer: € 12 000 for advertising opportunities.
Varian Medical Systems International AG
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centres and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs over 6,100 people, located at manufacturing sites, sales and support offices worldwide.
Premium Educational Grant
Caris Life Sciences
St. Jakobsstrasse 199
Tel: +41 61 317 02 00
Caris Life Sciences is a leading biosciences company focused on fulfilling the promise of personalised medicine. Caris’ Molecular Intelligence™ Service (MI Profile™) correlates molecular data generated from a patient’s tumour with biomarker/drug associations derived from the world’s leading clinical cancer literature. This service uses the most advanced and clinically-relevant technologies to provide physicians with information to aid in the selection of personalised cancer treatments more likely to work for each patient. Headquartered in the Dallas metroplex, Caris Life Sciences offers services throughout the United States, Europe, and other international markets.